U46619
 | |
| Names | |
|---|---|
| IUPAC name
(Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid | |
| Identifiers | |
56985-40-1  | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL357834  |
| ECHA InfoCard | 100.164.944 |
| 1888 | |
| PubChem | 5311493 |
| |
| Properties | |
| C21H34O4 | |
| Molar mass | 350.49 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
U46619 is a stable synthetic analog of the endoperoxide prostaglandin PGH2 first prepared in 1975,[1] and acts as a thromboxane A2 (TP) receptor agonist.[2] It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations.[3] and exhibits many properties similar to thromboxane A2, including shape change and aggregation of platelets [4] and smooth muscle contraction. U46619 is a vasoconstrictor that mimics the hydroosmotic effect of vasopressin.[5]
References
- ↑ Bundy, G. L. (1975). "Synthesis of prostaglandin endoperoxide analogs". Tetrahedron Letters. 24 (24): 1957–1960. doi:10.1016/S0040-4039(00)72333-1.
- ↑ "U 46619". www.tocris.com.
- ↑ "U 46619". www.tocris.com.
- ↑ Liel, N.; Mais, D.E.; Halushka, P.V (1987). "Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets". Prostaglandins. 33: 789–797. doi:10.1016/0090-6980(87)90107-9.
- ↑ Burch, Ronald M.; Halushka, Perry V. (1983). "Calcium-45 fluxes in isolated toad bladder epithelial cells: effects of agents which alter water or sodium transport". Journal of Pharmacology and Experimental Therapeutics. 224 (1): 108–17. PMID 6294273.
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.